Skip to main content

Advertisement

SpringerLink
Log in

Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA et al (2013) Acute myeloid leukemia, version 2.2013. J Natl Compr Cancer Netw 11(9):1047–1055

    Google Scholar 

  2. Klastersky J (2004) Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 39(Suppl 1):S32–S37

    Article  PubMed  Google Scholar 

  3. Harousseau JL, Witz B, Lioure B, Hunault-Berger M, Desablens B, Delain M et al (2000) Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. J Clin Oncol 18(4):780–787

    CAS  PubMed  Google Scholar 

  4. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G et al (1997) A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Int Acute Myeloid Leuk Study Group Blood 90(12):4710–4718

    CAS  Google Scholar 

  5. Bradley AM, Deal AM, Buie LW, Van DH (2012) Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor. Pharmacotherapy 32(12):1070–1077. doi:10.1002/phar.1150

    Article  CAS  PubMed  Google Scholar 

  6. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al (2006) Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24(19):3187–3205

    Article  CAS  PubMed  Google Scholar 

  7. Roskos LK, Lum P, Lockbaum P, Schwab G, Yang BB (2006) Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol 46(7):747–757

    Article  CAS  PubMed  Google Scholar 

  8. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14(1):29–35

    Article  CAS  PubMed  Google Scholar 

  9. Holmes FA, O’Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20(3):727–731

    Article  CAS  PubMed  Google Scholar 

  10. Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R et al (2003) Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma 44(9):1503–1508

    Article  CAS  PubMed  Google Scholar 

  11. Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J et al (2003) Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 21(3):514–519

    Article  CAS  PubMed  Google Scholar 

  12. Wolf M, Bentley M, Marlton P, Horvath N, Lewis ID, Spencer A et al (2006) Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma 47(11):2344–2350

    Article  CAS  PubMed  Google Scholar 

  13. Lane SW, Crawford J, Kenealy M, Cull G, Seymour JF, Prince HM et al (2006) Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leuk Lymphoma 47(9):1813–1817

    Article  CAS  PubMed  Google Scholar 

  14. Braess J, Spiekermann K, Staib P, Gruneisen A, Wormann B, Ludwig WD et al (2009) Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood 113(17):3903–3910. doi:10.1182/blood-2008-07-16284215

    Article  CAS  PubMed  Google Scholar 

  15. Derbel O, Cannas G, Le QH, Elhamri M, Chelghoum Y, Nicolas-Virelizier E et al (2010) A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule. Hematology 15(3):125–131. doi:10.1179/102453309x1258334711365416

    Article  CAS  PubMed  Google Scholar 

  16. Sierra J, Szer J, Kassis J, Herrmann R, Lazzarino M, Thomas X et al (2008) A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer 8:195. doi:10.1186/1471-2407-8-195

    Article  PubMed Central  PubMed  Google Scholar 

  17. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P et al (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer Leuk Group B N Engl J Med 331(14):896–903

    Article  CAS  Google Scholar 

  18. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 52(4):e56–e93. doi:10.1093/cid/cir073

    Article  PubMed  Google Scholar 

  19. Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694

    Article  CAS  PubMed  Google Scholar 

  20. Schlenk RF, Dohner K, Groner S, Hartmann PC, Krautner J, Ganser A et al (2006) Impact of pegfilgrastim on hematological reconstitution and incidence of neutropenic fever after consolidation therapy with high-dose cytarabine in acute myeloid leukemia: comparative analysis between AMLSG 07–04 and the German AML Intergroup Trial. blood (ASH annual meeting abstracts) 108: Abstract 2020

  21. Lowenberg B, Pabst T, Vellenga E, Van PW, Schouten HC, Graux C et al (2011) Cytarabine dose for acute myeloid leukemia. N Engl J Med 364:1027–1036. doi:10.1056/NEJMoa1010222

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Department of Haematology, Singapore General Hospital

Source of support

Roche Singapore provided 60 vials of pegylated filgrastim for the study at a 10 % discount.

Conflict of interest

Roche Singapore was not involved in the study apart from supplying pegfilgrastim at a discounted price and played no role in the design and conduct of the study, statistical analysis of the data or writing of the manuscript.

Author information

Authors and Affiliations

  1. Department of Haematology, Singapore General Hospital, Outram Road, Singapore, 169608, Singapore

    Grace Kam, Richard Yiu, Yvonne Loh, Ai Leen Ang, Ling Ling Yueh, Yeow Tee Goh & Gee Chuan Wong

  2. Asian American Blood and Marrow Transplant Centre, 6A Napier Road, Gleneagles Hospital, Annexe Block #05-36C, Singapore, 258500, Singapore

    Yvonne Loh

  3. Blood Services Group, Health Sciences Authority, 11 Outram Road, Singapore, 169078, Singapore

    Ai Leen Ang

Authors
  1. Grace Kam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Yiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yvonne Loh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ai Leen Ang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ling Ling Yueh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yeow Tee Goh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gee Chuan Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Grace Kam.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kam, G., Yiu, R., Loh, Y. et al. Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy. Support Care Cancer 23, 643–649 (2015). https://doi.org/10.1007/s00520-014-2417-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-014-2417-7

Keywords

Search

Navigation